Caris Life Sciences vs Vesta
Valar and Caris sell to separate specialists. A urologist with a non-muscle-invasive bladder cancer patient orders Vesta BCGPredict, which the vendor says runs on routine H&E slides in a CLIA-certified laboratory and reports about three days after the sample arrives. The vendor says biomarker-present patients face 2x the risk of non-response. Vesta's PubMed papers carry a Valar affiliation, and openFDA 510(k) queries under Valar and Vesta returned nothing for Valar Labs.
A medical oncologist whose patient needs a companion diagnostic orders from Caris. MI Cancer Seek holds PMA P240010, approved November 5, 2024, and its page lists claims tied to Piqray, Vectibix, Braftovi, Keytruda and Jemperli. The same page lists GPSai and FOLFIRSTai under professional services, outside the approved scope.
The Caris homepage and MI Cancer Seek page give no price, nor does the Vesta page.
Pathology · Reviewed November 2, 2026
Caris Life Sciences
by Caris Life Sciences · founded 2008
FDA-approved MI Cancer Seek tumor profiling test for oncologists. The GPSai tissue-of-origin AI is a lab service outside that approval.
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
When to pick each one
Caris Life Sciences
- PMA-approved MI Cancer Seek, November 2024
- Companion-diagnostic claims for Piqray, Vectibix and Keytruda
- 228-gene sequencing plus MSI and TMB
Vesta
- Vesta BCGPredict for non-muscle-invasive bladder cancer
- Vendor says report arrives about 3 days after receipt
- Runs on routine H&E slides
Score
Each row shows points earned of points available under the published rubric.
Caris Life Sciences
65of 100
Vesta
16of 100
| Dimension | Caris Life Sciences | Vesta | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 21 / 21 | 8.4 / 21 | +12.6 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Caris Life Sciences
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Caris Life Sciences
FDA decisions
P240010 (opens in new tab)PMA2024-11-05
MI Cancer Seek
Peer-reviewed
5 PubMed records name Caris Life Sciences.
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (opens in new tab)
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program. (opens in new tab)
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. (opens in new tab)
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Caris Life Sciences | Vesta |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2008 | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.